Amneal launches brekiya® – the first and only dhe autoinjector for adults with migraine with or without aura and cluster headaches

Bridgewater, n.j., oct. 27, 2025 (globe newswire) -- amneal pharmaceuticals, inc. (nasdaq: amrx) (“amneal” or the “company”) today announced the u.s. commercial launch of brekiya® (dihydroergotamine mesylate) injection, the first and only ready-to-use dihydroergotamine (dhe) autoinjector approved for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.1,2 the brekiya autoinjector is now available by prescription exclusively through walgreens specialty pharmacy and sterling specialty pharmacy.
AMRX Ratings Summary
AMRX Quant Ranking